Accumulated assignments to resolve when getting clinical studies done in China

For difficulties to conduct clinical studies in China, people picked: devaluation of clinical studies at hospitals, financial opacity and immaturity of the IRB review process.

At the KOREA PHARM & BIO 2018 on the 18th, difficulties that any pharmaceutical company might face before/after entering the Chinese pharmaceutical market were introduced.

A lecturer, Ascentage Pharma Vice President Zhu...